the difference between semaglutide and tirzepatide Comparative safety side effects of and tirzepatide: Implications for clinical decision-making in obesity management Semaglutide vs. Tirzepatide… what's the

GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity

Most users had #overweight or #obesity, and only 23% had a #diabetes diagnosis, suggesting weight reduction as the main reason for use.

As presented at the American Diabetes Association Meeting: this randomized phase 2b trial in 230 adults with overweight or obesity shows that aleniglipron, an oral small-molecule GLP1-RA, led to up to 11.3% body-weight loss compared with placebo after 36 weeks of treatment.

The anti-inflammatory effect could be one of the mechanisms by which semaglutide reduces cardiovascular risk in patients with type 2 diabetes mellitus (T2DM) and/or obesity

A 55-day review timeline compared to the standard 10-12 months is not just an administrative achievement

Here's advice from aRegistered Dietitian.